Table 2.
Upregulated lipids, 25 ng/mL | |||||||||
Strain | Time (min.) | FA | PR | SP | ST | GP | PK | GL | SL |
MG1655 | 30 | 1 | 0 | 6 | 1 | 12 | 0 | 1 | 0 |
60 | 12 | 4 | 2 | 0 | 4 | 0 | 1 | 0 | |
DPB635 | 30 | 30 | 0 | 3 | 0 | 0 | 0 | 2 | 0 |
60 | 20 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |
DPB636 | 30 | 1 | 0 | 3 | 0 | 0 | 0 | 5 | 0 |
60 | 8 | 1 | 0 | 2 | 3 | 0 | 0 | 0 | |
Downregulated lipids, 25 ng/mL | |||||||||
Strain | Time (min.) | FA | PR | SP | ST | GP | PK | GL | SL |
MG1655 | 30 | 1 | 0 | 1 | 1 | 3 | 0 | 1 | 1 |
60 | 114 | 52 | 28 | 72 | 139 | 1 | 18 | 0 | |
DPB635 | 30 | 0 | 1 | 2 | 1 | 15 | 0 | 1 | 0 |
60 | 0 | 1 | 2 | 1 | 15 | 0 | 1 | 1 | |
DPB636 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
60 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Upregulated lipids, 50 ng/mL | |||||||||
Strain | Time (min.) | FA | PR | SP | ST | GP | PK | GL | SL |
MG1655 | 30 | 3 | 1 | 1 | 1 | 13 | 0 | 2 | 1 |
60 | 7 | 1 | 1 | 0 | 5 | 0 | 1 | 0 | |
DPB635 | 30 | 19 | 0 | 3 | 1 | 0 | 1 | 0 | 0 |
60 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | |
DPB636 | 30 | 5 | 0 | 1 | 0 | 5 | 5 | 3 | 0 |
60 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
Downregulated lipids, 50 ng/mL | |||||||||
Strain | Time (min.) | FA | PR | SP | ST | GP | PK | GL | SL |
MG1655 | 30 | 2 | 4 | 0 | 3 | 5 | 0 | 1 | 0 |
60 | 15 | 11 | 9 | 15 | 104 | 0 | 11 | 0 | |
DPB635 | 30 | 2 | 0 | 1 | 1 | 18 | 0 | 0 | 1 |
60 | 0 | 1 | 0 | 1 | 3 | 0 | 0 | 0 | |
DPB636 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
60 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |